JP2022547718A5 - - Google Patents
Info
- Publication number
- JP2022547718A5 JP2022547718A5 JP2022516402A JP2022516402A JP2022547718A5 JP 2022547718 A5 JP2022547718 A5 JP 2022547718A5 JP 2022516402 A JP2022516402 A JP 2022516402A JP 2022516402 A JP2022516402 A JP 2022516402A JP 2022547718 A5 JP2022547718 A5 JP 2022547718A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025135892A JP2025183231A (ja) | 2019-09-13 | 2025-08-18 | 抗ｃｄ３７１抗体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900118P | 2019-09-13 | 2019-09-13 | |
| US62/900,118 | 2019-09-13 | ||
| US201962936913P | 2019-11-18 | 2019-11-18 | |
| US62/936,913 | 2019-11-18 | ||
| PCT/US2020/050380 WO2021050857A1 (en) | 2019-09-13 | 2020-09-11 | Anti-cd371 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025135892A Division JP2025183231A (ja) | 2019-09-13 | 2025-08-18 | 抗ｃｄ３７１抗体およびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022547718A JP2022547718A (ja) | 2022-11-15 |
| JP2022547718A5 true JP2022547718A5 (https=) | 2025-02-06 |
| JPWO2021050857A5 JPWO2021050857A5 (https=) | 2025-02-06 |
| JP7796008B2 JP7796008B2 (ja) | 2026-01-08 |
Family
ID=74866534
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516402A Active JP7796008B2 (ja) | 2019-09-13 | 2020-09-11 | 抗ｃｄ３７１抗体およびその使用 |
| JP2025135892A Pending JP2025183231A (ja) | 2019-09-13 | 2025-08-18 | 抗ｃｄ３７１抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025135892A Pending JP2025183231A (ja) | 2019-09-13 | 2025-08-18 | 抗ｃｄ３７１抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220195064A1 (https=) |
| EP (1) | EP4028422A4 (https=) |
| JP (2) | JP7796008B2 (https=) |
| KR (1) | KR20220069961A (https=) |
| CN (1) | CN114641503B (https=) |
| AU (1) | AU2020346886A1 (https=) |
| BR (1) | BR112022004603A2 (https=) |
| CA (1) | CA3154387A1 (https=) |
| IL (1) | IL291280A (https=) |
| MX (1) | MX2022003074A (https=) |
| WO (1) | WO2021050857A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023002392A1 (en) * | 2021-07-20 | 2023-01-26 | Abl Bio Inc. | Anti-cll-1/anti-cd3 bispecific antibodies and uses thereof |
| EP4584283A1 (en) | 2022-11-14 | 2025-07-16 | Caribou Biosciences, Inc. | Anti-cll-1 chimeric antigen receptors, engineered cells and related methods |
| WO2025193609A1 (en) | 2024-03-11 | 2025-09-18 | Caribou Biosciences, Inc. | Methods and compositions for cost-effective assessment of nucleic acid transcripts and isoforms in cells |
| WO2026024468A1 (en) | 2024-07-26 | 2026-01-29 | Caribou Biosciences, Inc. | Modular linked chimeric antigen receptors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ543635A (en) * | 2003-06-25 | 2008-05-30 | Crucell Holland Bv | Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML |
| CA2618796C (en) * | 2005-08-11 | 2018-01-02 | Arpi Matossian-Rogers | Peptides for treatment and diagnosis of autoimmune disease |
| EP2975057A1 (en) * | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
| ES2650224T3 (es) * | 2007-08-21 | 2018-01-17 | Amgen, Inc. | Proteínas de unión al antígeno C-FMS humano |
| JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| EP3453723B1 (en) * | 2012-01-31 | 2021-08-11 | Regeneron Pharmaceuticals, Inc. | Anti-asic1 antibodies and uses thereof |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| WO2016069549A1 (en) * | 2014-10-28 | 2016-05-06 | Albert Einstein College Of Medicine, Inc. | Multi-specific antibodies for cross-neutralization of multiple filovirus glycoproteins |
| WO2015174978A1 (en) * | 2014-05-15 | 2015-11-19 | R-Pharm Overseas, Inc. | Antibodies against human receptor integrin alpha-4 |
| EP3221351B1 (en) * | 2014-11-19 | 2024-11-13 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for cancer treating conditions relating to over expressions of epha2 |
| SI3115376T1 (sl) * | 2015-07-10 | 2018-12-31 | Merus N.V. | Humana protitelesa, ki vežejo CD3 |
| CA2997444A1 (en) * | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
| CN108290955A (zh) * | 2015-11-24 | 2018-07-17 | 塞勒兰特治疗公司 | 人源化抗-cll-1抗体 |
| RU2019121662A (ru) * | 2016-12-16 | 2021-01-18 | Мерк Патент Гмбх | Способы использования галектин-3-связывающего белка, обнаруживаемого в моче, для мониторинга тяжести и прогрессирования волчаночного нефрита |
| CA3154389A1 (en) * | 2019-09-13 | 2021-03-18 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting cd371 and uses thereof |
| KR20240087985A (ko) * | 2022-12-13 | 2024-06-20 | 엘지디스플레이 주식회사 | 표시장치 |
-
2020
- 2020-09-11 JP JP2022516402A patent/JP7796008B2/ja active Active
- 2020-09-11 CA CA3154387A patent/CA3154387A1/en active Pending
- 2020-09-11 MX MX2022003074A patent/MX2022003074A/es unknown
- 2020-09-11 CN CN202080077194.9A patent/CN114641503B/zh active Active
- 2020-09-11 BR BR112022004603A patent/BR112022004603A2/pt unknown
- 2020-09-11 EP EP20863987.2A patent/EP4028422A4/en active Pending
- 2020-09-11 AU AU2020346886A patent/AU2020346886A1/en active Pending
- 2020-09-11 WO PCT/US2020/050380 patent/WO2021050857A1/en not_active Ceased
- 2020-09-11 KR KR1020227012176A patent/KR20220069961A/ko not_active Ceased
-
2022
- 2022-03-10 IL IL291280A patent/IL291280A/en unknown
- 2022-03-11 US US17/692,979 patent/US20220195064A1/en active Pending
-
2025
- 2025-08-18 JP JP2025135892A patent/JP2025183231A/ja active Pending